Fennec Pharmaceuticals Inc - FENC STOCK NEWS

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has scheduled the release of its full year and fourth quarter 2024 financial results for Monday, March 10, 2025, before U.S. financial markets open. The commercial stage specialty pharmaceutical company will follow the release with a management-hosted conference call and webcast to discuss financial and business results.

Interested parties can access the live webcast through the company's website at www.fennecpharma.com under the Investors & Media section's News & Events/Event Calendar page. Participants are advised to connect at least 15 minutes before the conference call to allow time for any necessary software downloads. A replay of the webcast will be available on the company's website for thirty days following the event.

Fennec Pharmaceuticals (NASDAQ: FENC) announced the commercial launch of PEDMARQSI in Germany through Norgine Pharmaceuticals. PEDMARQSI is the first and only approved therapy in the EU and UK for preventing hearing loss caused by cisplatin chemotherapy in pediatric cancer patients aged 1 month to <18 years with localized, non-metastatic solid tumors.

The launch follows a March 2024 exclusive licensing agreement with Norgine for Europe, Australia, and New Zealand. Fennec received $43 million upfront and could receive up to $230 million in additional milestone payments, plus double-digit tiered royalties starting in mid-teens and growing to mid-twenties.

Clinical trials demonstrated that PEDMARQSI reduced cisplatin-induced hearing loss by approximately 50% compared to cisplatin alone. The drug received European Commission marketing authorization in June 2023 under PUMA, with 10 years of data and market protection.

Fennec Pharmaceuticals (NASDAQ:FENC) announced that PEDMARQSI® has received a positive recommendation from NICE for use in England and Wales. The drug is the first and only treatment available within NHS for preventing cisplatin-induced hearing loss in children and young people aged 1 month to 17 years.

Two Phase 3 trials demonstrated approximately 50% reduction in cisplatin-induced ototoxicity compared to cisplatin alone. This addresses a significant unmet need as there were no previous preventative treatments available.

The announcement follows Fennec's March 2024 licensing agreement with Norgine Pharmaceuticals for commercialization in Europe, Australia, and New Zealand. The deal included a $43 million upfront payment and potential additional payments up to $230 million, plus double-digit tiered royalties starting in mid-teens.

Fennec Pharmaceuticals (NASDAQ:FENC) announced the early repayment of $13 million of its approximately $32 million outstanding convertible debt facility with Petrichor Healthcare Capital Management. This repayment, funded entirely with available cash, reduces the convertible debt to approximately $19 million with maturity in September 2027.

The strategic move will eliminate approximately $1.5 million in annual interest expense and remove the potential equity overhang of approximately 1.6 million shares. The company confirms its cash position remains sufficient to fund planned operations into 2026.

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced its participation in the upcoming virtual H.C. Wainwright @ Home Fireside Chat Series. The event is scheduled for Monday, December 16, 2024, at 11:00 a.m. ET. The commercial stage specialty pharmaceutical company will provide a live webcast of the presentation, which will be accessible through their investor relations website. An archived version of the webcast will be made available on the company's website following the event for those unable to attend the live presentation.

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference. The event will take place on November 19, 2024, at the Sheraton New York Times Square Hotel in New York City. The company's management team will be available for one-on-one meetings throughout the conference. Fennec Pharmaceuticals, a commercial stage specialty pharmaceutical company, will use this platform to engage with investors and present their business updates.

Fennec Pharmaceuticals (NASDAQ:FENC) reported Q3 2024 net product sales of $7.0 million, up from $6.5 million in Q3 2023. The company achieved over 90% reimbursement for PEDMARK in the AYA population. Despite increased sales, the company recorded a net loss of $5.7 million ($0.21 per share) compared to $1.9 million loss in Q3 2023. Operating expenses increased to $12.2 million from $7.5 million year-over-year. The company maintains a strong cash position of $40.3 million, expected to fund operations into at least 2026.

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, has scheduled its third quarter 2024 financial results release for Thursday, November 7, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial and business results. Interested parties can register for the conference call through a provided link, which will supply a dial-in number and unique PIN. A webcast replay will be available on the company's website for thirty days following the call.

Fennec Pharmaceuticals (NASDAQ: FENC) announced three key executive appointments to strengthen its leadership team. Pierre S. Sayad joins as Chief Medical Officer, bringing 22 years of experience and involvement in launching nine novel drugs. Terry Evans becomes Chief Commercial Officer with over 25 years of pharmaceutical industry experience. Christiana Cioffi assumes the role of Chief Strategy Officer, contributing 20 years of expertise in strategy and marketing, particularly in oncology and rare diseases. These appointments aim to accelerate the commercialization of PEDMARK, the company's FDA-approved therapy for reducing ototoxicity risk in pediatric patients receiving cisplatin treatment.